Welcome to the e-CCO Library!

P401: Confocal laser endomicroscopy predicts response in patients with acute inflammatory bowel disease undergoing anti-integrin therapy with vedolizumab
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Ellrichmann*1, J. Bethge1, G. Aust1, A. Arlt1, B. Brandt1, S. Zeissig1, 2, S. Nikolaus1, K. Aden1, S. Schreiber1

Created: Friday, 22 February 2019, 9:49 AM
P401: Reduction of dosing intervals is the preferable dose optimisation strategy for infliximab to suppress formation of anti-drug antibodies
Year: 2018
Source: ECCO '18 Vienna
Authors:

W. Reinisch1*, A. Eser1, S. Schreiber2, H. Kim3, D. Mould4

Created: Thursday, 21 February 2019, 9:14 AM
P401: Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Lamb, C.A.(1,2);Sebastian, S.(3,4);Kent, A.J.(5);Segal, J.P.(6);Gonzalez, H.A.(3,4);Brookes, M.J.(7,8);Mehta, S.J.(9);Subramanian, S.(10,11);Bhala, N.(12,13);Hicks, L.C.(6);Conley, T.E.(10);Patel, K.V.(14);Walker, G.J.(15);Kennedy, N.A.(16,17);
Created: Wednesday, 2 June 2021, 4:12 PM
P401: Tofacitinib tissue exposure correlates with endoscopic outcome
Year: 2022
Source: ECCO'22
Authors: Verstockt., B.(1,2);Alsoud, D.(2);van Oostrom, J.(3);Smith, J.(4);Stylli, J.(4);Singh, S.(4);van Gennep, S.(3);Rahimian, P.(4);Sabino, J.(1,2);Ferrante, M.(1,2);Singh, S.(4);D'Haens, G.(1);Vermeire, S.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P402 Prediction of emergency department re-visit among Crohn’s disease patients: a retrospective study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

H. Mahajna1, Y. Barash2, B. Ungar1, S. Soffer2, S. Ben-Horin1, E. Klang2, U. Kopylov1

Created: Thursday, 30 January 2020, 10:12 AM
P402: A novel high-dose mesalazine tablet is as effective as conventional low-dose mesalazine tablets in inducing remission in patients with mildly to moderately active ulcerative colitis (UC): A double-blind, double-dummy, multicentre, randomised trial
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Dignaß*1, R. Schnabel2, J. Romatowski3, V. Pavlenko4, A. Dorofeyev5, J. Derova6, L. Jonaitis7, T. Nacak8, R. Greinwald8

Created: Friday, 22 February 2019, 9:49 AM
P402: A Pilot Study on the Effect of Colesevelam on the Microbiome in Primary Terminal Ileal Resected Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kumar, A.(1)*;Quraishi, M.N.(2);Al-Hassi, H.O.(3);Elasrag, M.(4);Segal, J.P.(5);Jain, M.(1);Steed, H.(1);Butterworth, J.(6);Farmer, A.(7);McLaughlin, J.(8);Beggs, A.(4);Brookes, M.(1);
Created: Friday, 14 July 2023, 11:05 AM
P402: Discontinuation of short-term infliximab maintenance therapy in patients with Crohn's disease: outcomes and risk factors associated with relapse
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zheng D.1, Mao R.1, Chen B.1, Feng T.1, Ben-Horin S.2, Chen M.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P402: Incidence and outcomes of herpes zoster in the ozanimod phase 3 ulcerative colitis and relapsing multiple sclerosis clinical program
Year: 2022
Source: ECCO'22
Authors: Siegmund, B.(1);Melmed, G.Y.(2);Irving, P.M.(3);Pai, A.(4);Patel, A.(4);Sheffield, J.K.(4);Caldera, F.(5);Cree, B.A.C.(6);Dubinsky, M.C.(7);
Created: Friday, 11 February 2022, 3:52 PM
P402: Interstitial and granulomatous lung disease in inflammatory bowel disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Eliadou1*, J. Moleiro2, D.G. Ribaldone3, M. Astegiano3, K. Rothfuß4, C. Taxonera5, B. Verstockt6, F. Ghalim7, F. Carbonnel7, S. Festa8, A. Berrozpe9, L. Maia10, E. Savarino11, P. Ellul12, E. Zagorowicz13, S. Vavricka14, M. Calvo15, I. Koutroubakis16, F. Hoentjen17, L. Fernández Salazar18, F. Callela19, F. Cañete Pizarro20, K. Soufleris21, E. Sonnenberg22, M. Cavicchi23, G. Fiorino24,25

Created: Thursday, 21 February 2019, 9:14 AM
P402: Is co-trimoxazole prophylaxis necessary for Inflammatory Bowel Disease patients receiving triple immunosuppression?
Year: 2021
Source: ECCO'21 Virtual
Authors: Phillips, G.(1);Moore-Gillan, C.(1);Mohamed, Z.(1);Mikin, P.(1);Peake, S.(1);Hicks, L.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P402: Systemic steroids vs. local acting steroids: Relative risk for corticosteroid-related adverse events
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Timeus1, R. Hofmann*2

Created: Friday, 22 February 2019, 9:41 AM
P403 Post hoc examination of VISIBLE 1 data for baseline predictors of response to 2 or 3 IV doses of vedolizumab for adults with moderate-to-severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. Sandborn1, E.V. Loftus Jr2, F. Baert3, J. Jansson4, J. Chen4, N. Candela5, K. Lasch5, K. Kisfalvi4

Created: Thursday, 30 January 2020, 10:12 AM
P403: Adherence to vaccination recommendations in patients with Inflammatory Bowel Disease: a long way for improving.
Year: 2021
Source: ECCO'21 Virtual
Authors: Ferreiro Iglesias, R.(1);Hernández Camba, A.(2);Saldaña, R.(3);Rodríguez-Lago, I.(4);Zabana, Y.(5);Barreiro-de Acosta , M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P403: Combined therapy with anti-TNF and immunomodulator is superior to monotherapy for postoperative prophylaxis in Crohn’s disease after intestinal resection: a retrospective analysis from a tertiary centre
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. O’Connor*1, J. Taylor1, N. Scott2, C. Selinger1, J. Hamlin1, A. Ford1, 3

Created: Friday, 22 February 2019, 9:49 AM
P403: Golimumab therapy for ulcerative colitis – an Irish multicentre experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

O'Connell J.*1, Rowan C.2, Chan G.3, Harkin G.4, Parihar V.5, Layden J.3, Patchett S.5, Stack R.6, MacMathuna P.3, O'Toole A.5, Ryan B.7, MacCarthy F.1, McKiernan S.1, Doherty G.2, Eagan L.4, Kevans D.1

Created: Wednesday, 20 February 2019, 10:36 AM
P403: Intravenous iron infusion in inflammatory bowel disease: efficacy and ferro-economics
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Ranjan*1, D. Rayner1, F. Maw1, A. Dhar1

Created: Friday, 22 February 2019, 9:41 AM
P403: The role of Organic Cation Transporter (OCTN)-1 in predicting individual response to therapy in Ulcerative Colitis: towards a personalized approach.
Year: 2022
Source: ECCO'22
Authors: Puca, P.(1);Capobianco, I.(1);Petito, V.(1);Masi, L.(1);Fidaleo, M.(2);Del Chierico , F.(3);Palucci, I.(4);Lopetuso, L.R.(1);Laterza, L.(1);Settanni, C.R.(1);Parisio, L.(1);Bibbò, S.(1);Pugliese, D.(1);Armuzzi, A.(1);Pani, G.(5);Gasbarrini, A.(1);Scaldaferri, F.(1);
Created: Friday, 11 February 2022, 3:52 PM
P403: Therapeutic compliance in patients with chronic inflammatory bowel disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hajlaoui, A.(1)*;Sabbah, M.(2);Bibani, N.(2);Jlassi, H.(2);Bellil , N.(2);Lassoued, K.(2);Trad, D.(2);Gargouri, D.(2);
Created: Friday, 14 July 2023, 11:05 AM
P403: Treatment naïve newly diagnosed patients with Crohn's disease have microbial dysbiosis correlated with disease activity and faecal calprotectin—results from a prospective inception cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Yanai1,2*, I. Goren3,4, L. Reshef5, L. Godny1,2, K. Yadgar1, K. Zonenesain1, I. Dotan2,3

Created: Thursday, 21 February 2019, 9:14 AM